Follow Binaytara on FacebookFollow Binaytara on XFollow Binaytara on LinkedinFollow Binaytara on BlueskyFollow Binaytara on Instagram
Binaytara logo
  • About Us
  • CME Conferences
  • Funding Opportunities
  • Projects
  • Get Involved
  • News
Thursday, September 10, 2026
The Cancer News

AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER

All Articles
Cancer Education
  • Resources for Cancer Patients
Perspectives
Clinical Breakthroughs & Research
Health Equity
About Us
  • Contributors
  • Ethics and Disclosure Policy
  • Editorial Standards & Corrections Policy
Article Submission
The Cancer News>Cancer Education>New Targets in Squamous NSCLC: Old Mechanisms, Novel Approaches, and Two Phase 3 Trials Worth Watching

New Targets in Squamous NSCLC: Old Mechanisms, Novel Approaches, and Two Phase 3 Trials Worth Watching

New Targets in Squamous NSCLC: Old Mechanisms, Novel Approaches, and Two Phase 3 Trials Worth Watching

Browse by Topics

Cancer EducationPerspectivesHealth EquityHealth PolicyResources for Cancer PatientsResearch
More from Cancer Education
Castleman Disease: Redefining the Spectrum Between "One Lymph Node" and "Many"

Castleman Disease: Redefining the Spectrum Between "One Lymph Node" and "Many"

September 4, 2026

EGFR Resistance Is Genuinely Heterogeneous, and That Should Change How We Study New Drugs

EGFR Resistance Is Genuinely Heterogeneous, and That Should Change How We Study New Drugs

September 3, 2026

HIF-2 Alpha Inhibition in Kidney Cancer: From Adjuvant Belzutifan to the Post-Immunotherapy Setting

HIF-2 Alpha Inhibition in Kidney Cancer: From Adjuvant Belzutifan to the Post-Immunotherapy Setting

September 3, 2026

Daraxonrasib and the RAS(ON) Revolution in Pancreatic Cancer Treatment

Daraxonrasib and the RAS(ON) Revolution in Pancreatic Cancer Treatment

September 2, 2026

How to Treat Mantle Cell Lymphoma in 2026

How to Treat Mantle Cell Lymphoma in 2026

September 2, 2026

Resistance to KRAS Inhibitors Is Multilayered, and Lineage Plasticity Deserves More Attention

Resistance to KRAS Inhibitors Is Multilayered, and Lineage Plasticity Deserves More Attention

Early Relapse DLBCL: A Case-Based Guide to CAR T-Cell Referral, Product Selection, and Post-CAR-T Sequencing

Early Relapse DLBCL: A Case-Based Guide to CAR T-Cell Referral, Product Selection, and Post-CAR-T Sequencing

Share Article

Get the Quick Bites delivered to your inbox daily

Binaytara logo

19-years of advocating, educating and innovating to improve Cancer Care.

Useful Links

  • News and Stories
  • OncoBlast
  • Careers
  • Donate

US Address

  • Binaytara
  • 3380 146th Pl SE, Suite 340
  • Bellevue, WA 98007 USA

Nepal Address

  • Binaytara Country Office
  • Kadam Chowk
  • Janakpur, NEPAL
  • _______
  • Binaytara Cancer Center
  • Janakpur, NEPAL

Legal

  • Privacy Policy

Binaytara is a 501(c)(3) not-for-profit organization. Our EIN number. is 26-1603676. © 2026, Binaytara. All rights reserved

Follow Binaytara on FacebookFollow Binaytara on BlueskyFollow Binaytara on LinkedinFollow Binaytara on YoutubeFollow Binaytara on TwitterFollow Binaytara on Instagram